UCB

Discover how UCB is championing a better future for women with epilepsy. From tackling info gaps to strategic collaborations, Andrea Wilkinson - Global Head of Epilepsy & Rare Syndromes Patient Engagement - takes us through how we are making a difference. https://lnkd.in/eMa8jD2f #Epilepsy #ExploringEpilepsies

At UCB, we're committed to elevating the standard of care by going beyond the science. Our FASTRAX program exemplifies this commitment, addressing the critical issue of delayed diagnosis of axial spondyloarthritis (axSpA). By leveraging our expertise, technology, and stakeholder collaboration, we're transforming the patient journey from the first signs of symptoms to timely diagnosis and treatment. Learn more about our innovative solutions and how we're making a real impact on the lives of those living with axSpA. #HealthcareInnovation #Rheumatology #PatientCare #FASTRAX #UCB https://lnkd.in/eje4iMtD

We are delighted to share that last night in London, UCB in partnership with Syneos Health, received a Highly Commended accolade in the Progress Award in Healthcare and Scientific Communications at the prestigious Communique Awards. Our work in AI Change Management was recognised for its progressive and people-first nature, increasing UCB’s adoption of generative AI technologies across communications to transform the way we deliver for patients and the business. This achievement highlights our commitment to innovation and the continuous advancement of healthcare communications. A big thank you to everyone involved in this journey. Let’s continue pushing boundaries and making a difference! #communique #communiqueawards24 #healthcommunications

Navigating the path to starting a family presents complex challenges for women living with epilepsy. Read more in this Exploring Epilepsies series on how we're helping drive change https://lnkd.in/eMa8jD2f #Epilepsy #ExploringEpilepsies

The scarcity of high-quality data on #ChronicDisease and pregnancy has far-reaching consequences. Hellen shares her experience navigating living with psoriasis while pregnant and breastfeeding. Hellen’s story underscores how many women living with a chronic disease are left to wonder and worry. Likewise, without good data, healthcare providers are at a loss in terms of advising their patients on the best course of action. New recommendations developed by the BRIDGE Commission, a multidisciplinary group of experts in the field of pregnancy and breastfeeding, provide practical, action-oriented solutions to overcome the information gaps that affect women living with chronic disease. Learn more and read the full report: https://lnkd.in/ekgvNzcp #WomensHealth #HealthEquity #BRIDGE4WomensHealth

In this era of rapid technological advancement, it's exciting to imagine what the future holds. Artificial Intelligence (AI) is stepping into the spotlight and promises to be game changing across the board.  However, adopting AI in the pharmaceutical industry is not without its hurdles. The integration of AI into existing systems and workflows necessitates a strategic approach. It's crucial to focus on areas where AI can have a significant impact, such as drug discovery and clinical trial design. Moreover, maintaining a human touch, especially during clinical trials, is essential for addressing participants' concerns and establishing trust.   Despite AI's transformative potential, healthcare remains fundamentally patient-centric. Balancing AI's impact with the human touch will be key to truly revolutionizing patient care and outcomes. Curious about the future of health? Roger Palframan, our Head of US Research, shares an insightful perspective on how AI is driving the sector to new peaks of innovation and efficiency – https://lnkd.in/eydA4Um9  

The synergy of AI and human expertise holds the key to a more efficient, patient-focused pharmaceutical industry. With continuous advancements and collaborative efforts, the potential for groundbreaking discoveries is limitless. Join us on this exciting journey to the future of pharma innovation, as Tero Laulajainen and UCB lead the way. Discover more about how AI is set to revolutionize our industry – click the link to read the full interview 👉 https://lnkd.in/dTB6bT8y #AI #PharmaInnovation #FutureOfPharma #PersonalizedMedicine #HealthTech #ClinicalTrials 

UCBCares® is the Service Center offered by UCB to support people living with a disease and their healthcare professionals during their treatment journey with a UCB medicine. UCBCares® does not replace the conversation or the medical advice of the treating doctor or is not meant to promote the medicines of UCB. #UCBCares, #Neurology, #Neurologicalcondition

Thanks Galliker Transport AG for the great collaboration. Together, we are making a difference and working towards reducing our environmental footprint. Congratulations on pushing boundaries in innovative e-transport solutions. #Sustainability #TeamUCB”

As we reflect on Dravet syndrome awareness month, we are inspired by the personal stories shared and the dedication shown by all those affected by this rare #epilepsy. We remain committed to driving DS awareness and progress. Learn more: https://t.co/eCfzWKbquX #dravetawareness